HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

deferiprone (CP20)

Subscribe to New Research on deferiprone

Also Known As:

CP20; 1,2-dimethyl-3-hydroxy-4-pyridinone; 1,2-dimethyl-3-hydroxypyrid-4-one; 1,2-dimethyl-3-hydroxypyridin-4-one; 3-hydroxy-1,2-dimethyl-4-pyridinone; Chiesi brand of deferiprone; DMOHPO; Ferriprox; Hdmpp cpd; Hdpp; L1 oral chelate; Swedish Orphan brand of deferiprone

Networked: 382 relevant articles (61 outcomes, 75 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 60
- 1-Ring Heterocyclic Compounds
  - Pyridines: 41
    - Pyridones: 10
      - deferiprone: 382

Experts

1.	Kontoghiorghes, George J: 29 articles (03/2015 - 01/2002)
2.	Kolnagou, Annita: 18 articles (01/2015 - 01/2002)
3.	Galanello, Renzo: 18 articles (06/2014 - 09/2002)
4.	Piga, Antonio: 15 articles (07/2013 - 09/2002)
5.	Maggio, Aurelio: 11 articles (07/2015 - 03/2002)
6.	Prossomariti, Luciano: 10 articles (08/2013 - 03/2006)
7.	Tricta, Fernando: 9 articles (10/2014 - 05/2003)
8.	Fucharoen, Suthat: 8 articles (05/2015 - 01/2006)
9.	Peng, Ching-Tien: 8 articles (07/2014 - 01/2006)
10.	Cianciulli, Paolo: 8 articles (08/2013 - 03/2002)

Related Diseases

1.	Iron Overload 11/01/2010 - "This study evaluated the safety and efficacy of a new liquid formulation of deferiprone for the treatment of transfusional iron overload in children 1-10 years old. " 11/01/2010 - "The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload." 11/01/2010 - "The results of this study show a favorable benefit/risk ratio of deferiprone oral solution for the treatment of young children with transfusional iron overload." 03/01/2010 - "The aims of this study were to investigate the efficacy and safety of deferiprone in a variety of pediatric hematologic and/or oncologic patients with a high iron overload. " 02/01/1997 - "Clinical trials are in progress in many centers worldwide that will provide further information on the long-term effectiveness of deferiprone as well as on the incidence of serious adverse effects in patients with iron overload. "
2.	beta-Thalassemia (Cooley's Anemia) 03/01/2006 - "Oral deferiprone (L1) appears to be promising in the treatment of beta-thalassemia major (TM) patients. " 03/01/2006 - "Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*." 01/01/2006 - "A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong." 04/01/2008 - "Our objective was to assess the long-term efficacy of deferiprone in patients with thalassemia major. " 09/01/2003 - "Based on our findings in a 1-year multicenter, prospective study of the safety and efficacy of deferiprone in patients with thalassemia major, we have extended the treatment period to 4 years. "
3.	Thalassemia 04/01/2013 - "Seventy-three pediatric patients with severe β thalassemias, age range 3.2-19 years, were recruited to a 1-year multicenter prospective, single arm, open label, dose escalating Phase III study of deferiprone to determine its clinical efficacy and safety. " 12/01/2012 - "The method was successfully applied to a pharmacokinetic study of deferiprone in six thalassemia patients." 04/01/1990 - "Studies of the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one in thalassemia patients." 12/01/2013 - "Routine radiographs of left wrist and hand done for bone age estimation in 40 children with thalassemia were evaluated and revealed unique radiographic changes in 13 children (10 males: 3 females) with previous or current deferiprone related arthropathy. " 12/01/2013 - "Distal ulnar changes in children with thalassemia and deferiprone related arthropathy."
4.	Siderosis 01/01/2009 - "Therapy combining deferiprone with DFO has proved effective in the management of severe cardiac siderosis. " 01/01/2013 - "Further studies are required to assess the clinical efficacy of deferiprone in superficial siderosis. " 01/01/2012 - "Prospectively designed efficacy studies are necessary to determine the clinical efficacy of deferiprone in superficial siderosis." 01/01/2012 - "Pilot safety trial of deferiprone in 10 subjects with superficial siderosis." 01/01/2013 - "The proposed deferiprone-based therapy has provided a paradigm for treating regional types of siderosis without affecting hematological parameters and systemic functions. "
5.	Cardiomyopathies (Cardiomyopathy) 07/01/2007 - "A 6-month treatment with 20 to 30 mg/kg/d deferiprone of 9 adolescent patients with no overt cardiomyopathy reduced R2* from 18.3 s(-1) (+/- 1.6 s(-1)) to 15.7 s(-1) (+/- 0.7 s(-1); P < .002), specifically in dentate nuclei and proportionally to the initial R2* (r = 0.90). " 01/01/1997 - "Patients with cardiomyopathy due to iron overload should be given intravenous DFX rather than deferiprone. " 01/01/2008 - "Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone." 01/01/2006 - "The incidence of cardiomyopathy was monitored in a 6-year follow-up study involving 56 transfused thalassemia patients treated with deferoxamine (DFO), deferiprone (L1) or their combination. " 01/01/2006 - "Combination therapy with deferoxamine and deferiprone has been shown to be more effective than either drug used alone in patients with beta-thalassemia major and symptomatic cardiomyopathy. "

Related Drugs and Biologics

1.	Iron
2.	Deferoxamine (Desferal)
3.	deferasirox
4.	Chelating Agents
5.	Isoflurophate (DFP)
6.	deferiprone (CP20)
7.	idebenone
8.	Iron Chelating Agents
9.	Lipid A
10.	1,2-diethyl-3-hydroxypyridin-4-one

Related Therapies and Procedures

1.	Chelation Therapy (Therapy, Chelation)
2.	Dacryocystorhinostomy
3.	Complementary Therapies (Alternative Medicine)
4.	Blood Transfusion (Blood Transfusions)
5.	Transplants (Transplant)